given the results published today in NEJM, it seems that this REACTING-sponsored multi-arm trial could skip the arm 2 (at least) https://t.co/0jnYTD8L1f
Klinisk studie, randomiserad: antivirala mot standardvård vid Covid-19. Ingen effekt jämfört med standardvård om denna antivirala behandling lades till. Länk till hela publikationen nedan.
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…
Seguimos buscando como meterle mano a esto.
RT @SIDPharm: New in NEJM! RCT (open label) of lopinavir/ritonavir in adult patients hospitalized for COVID19. Results: no benefit over ser…
RT @infecciosasryc: Artículo relevante en #CoVID19: https://t.co/R3t5DqStiC No se observa beneficio asociado al uso de lopinavir/r (14 días…
Disappointing results for Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 in today’s @NEJM https://t.co/gYmroK0q6w https://t.co/e45tngeBzt
RT @infecciosasryc: Artículo relevante en #CoVID19: https://t.co/R3t5DqStiC No se observa beneficio asociado al uso de lopinavir/r (14 días…
1 down, several more to go
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/bSxNUPydRH Despite the unfavorable result, I admire the speed to take a hypothesis to a RCT.
RT @bhalomanush: One day after Indian health ministry recommends anti-HIV drugs, these drugs fail in published clinical trials. https://t…
New in @NEJM. No significant difference in time to clinical improvement observed for 199 #COVID19 patients randomized to lopinavir-ritonavir vs. standard of care. Median time to improvement was 16 days in both groups. https://t.co/HlyAZDK5jt https://t.co/
Lopinavir–Ritonavir combination therapy ineffective in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/ewJMFZgByH
RT @mugecevik: 28/ 1st clinical trial of Lopinavir–Ritonavir in #COVID19: Among 199 seriously ill lab-confirmed cases, no significant benef…
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/iEMDTMwcdu 👎 Next
RT @mugecevik: 28/ 1st clinical trial of Lopinavir–Ritonavir in #COVID19: Among 199 seriously ill lab-confirmed cases, no significant benef…
RT @mugecevik: 28/ 1st clinical trial of Lopinavir–Ritonavir in #COVID19: Among 199 seriously ill lab-confirmed cases, no significant benef…
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
RT @MJA_Editor: #COVID2019AU “No benefit was observed with lopinavir–ritonavir treatment beyond standard care.” High quality randomised tri…
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
The worst thing about modern medical science is.. it's changing faster than our ability to learn.
RT @MJA_Editor: #COVID2019AU “No benefit was observed with lopinavir–ritonavir treatment beyond standard care.” High quality randomised tri…
FYI, A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/F0yLIQzAa0
Welp. So much for that one...
RT @mugecevik: 28/ 1st clinical trial of Lopinavir–Ritonavir in #COVID19: Among 199 seriously ill lab-confirmed cases, no significant benef…
RT @methodsmanmd: Trial of lopinavir/ritonavir in severe #COVID19 cases. Overall no benefit. But so important to be doing these types of…
RT @xsaezll: mala noticia, un tratamiento fallido: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https:…
RT @ClancyNeil: L-R trial out in NEJM. Hospitals pts, O2 sat </=94%. 1:1 vs standard care. n=99 L-R. Median age 58 years (IQR, 49 to 68…
👇👇👇👇👇👇
28/ 1st clinical trial of Lopinavir–Ritonavir in #COVID19: Among 199 seriously ill lab-confirmed cases, no significant benefit was observed with LOP/rtv (n=99) re clinical improvement or mortality or viral clearance vs. standard care (n=100) #COVID19Rx h
RT @infecciosasryc: Artículo relevante en #CoVID19: https://t.co/R3t5DqStiC No se observa beneficio asociado al uso de lopinavir/r (14 días…
Well there goes Kaletra for severe #COVID19. https://t.co/5JMdN9ez9f
RT @SIDPharm: New in NEJM! RCT (open label) of lopinavir/ritonavir in adult patients hospitalized for COVID19. Results: no benefit over ser…
RT @DrJeanneM: Just out today #COVID19 #Kaletra #treatment shows no benefit A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Seve…
RT @DomingoPascualF: lopinavir–ritonavir sin beneficio aparente en estudio pequeño de 200 pacientes frente a #COVID19 en @NEJM https://t.co…
Jammen....åååh!
RT @SIDPharm: New in NEJM! RCT (open label) of lopinavir/ritonavir in adult patients hospitalized for COVID19. Results: no benefit over ser…
RT @infecciosasryc: Artículo relevante en #CoVID19: https://t.co/R3t5DqStiC No se observa beneficio asociado al uso de lopinavir/r (14 días…
RT @methodsmanmd: Trial of lopinavir/ritonavir in severe #COVID19 cases. Overall no benefit. But so important to be doing these types of…
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe COVID-19. 28 day mortality not significantly lower vs standard of care (19.2% vs. 25.0%; difference, −5.8%; 95% CI, −17.3 to 5.7). 1/n https://t.co/Xlhjfixt2m
RT @infecciosasryc: Artículo relevante en #CoVID19: https://t.co/R3t5DqStiC No se observa beneficio asociado al uso de lopinavir/r (14 días…
L-R trial out in NEJM. Hospitals pts, O2 sat </=94%. 1:1 vs standard care. n=99 L-R. Median age 58 years (IQR, 49 to 68 years). 60% men (Table 1). No difference mortality, time to improve, RNA kinetics. MITT: L-R 1 day shorter to clinical improve. h
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
RT @vmcorman: "In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond stand…
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care https://t.co/meK6C59N9K
Artículo relevante en #CoVID19: https://t.co/R3t5DqStiC No se observa beneficio asociado al uso de lopinavir/r (14 días) en monoterapia. Ensayo abierto controlado en 199 pacientes con criterios de gravedad en Wuhan https://t.co/0kp2KqeTUG
RT @bealelab: @tulunsokit @rabpeel @NephJC Trial has just reported no benefit of Lopinavir/Ritonavir in NEJM. #nephjc https://t.co/CQZM79xh…
Great to see decently powered randomized clinical trial results starting to come out for #COVID19. Unfortunately this one was negative. Protease inhibitor Lopinavir–Ritonavir not helping adults with Severe Covid-19 https://t.co/G7y9ETpzfM
RT @vmcorman: "In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond stand…
RT @AndyBiotech: Here comes the data from first randomized trial for #COVID19 Unfortunately no benefit was observed with $ABBV lopinavir–…
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
@th3Derek @hereburgher Understandable. And not all the data coming out of China is suspect. For example they have already shown in one trial that a different set of repurposed drugs was not effective: https://t.co/IrhO5HV7T0
עוד אכזבה: התרופה האנטי-ויראלית לופינאביר/ריטונאביר, שמשמשת לטיפול בHIV, לא הועילה לחולי קוביד-19
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…
RT @boback: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 @nejm https://t.co/G1cSCEscnP
In hospitalized adult patients with severe #Covid-19, no benefit with lopinavir–ritonavir https://t.co/jXzhcJYCak
RT @xsaezll: mala noticia, un tratamiento fallido: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https:…
New in NEJM! RCT (open label) of lopinavir/ritonavir in adult patients hospitalized for COVID19. Results: no benefit over served with lopinavir/ritonavir treatment beyond standard of care, more GI side effects, & stopped early in 13 patients. #COVID19R
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…
Hot off the press via @NEJM. Open label RCT of N=199 (hospitalized, COVID+) received lopinavir-ritonavir vs standard care. Outcome = time to clinical improvement. HR 1.24 with 95% CI 0.90 - 1.72. Reported as "no benefit" but i want to remain optimistic! ht
RT @xsaezll: mala noticia, un tratamiento fallido: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https:…
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…
RT @vmcorman: "In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond stand…
RT @xsaezll: mala noticia, un tratamiento fallido: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https:…
lopinavir–ritonavir sin beneficio aparente en estudio pequeño de 200 pacientes frente a #COVID19 en @NEJM https://t.co/zh8OdAFeK5
Disappointing although somewhat intriguing. First randomized trial of anti virals (Lopinavir–Ritonavir) for COVID-19 completed in record time but negative https://t.co/h0TS4tE5DU
RT @bealelab: @tulunsokit @rabpeel @NephJC Trial has just reported no benefit of Lopinavir/Ritonavir in NEJM. #nephjc https://t.co/CQZM79xh…
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…
RT @vmcorman: "In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond stand…
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/qtNVfyjsQW
One down. In patients with severe #COVID19, no benefit was observed with #lopinavir–ritonavir treatment beyond standard care.
RT @methodsmanmd: Trial of lopinavir/ritonavir in severe #COVID19 cases. Overall no benefit. But so important to be doing these types of…
RT @MJA_Editor: #COVID2019AU “No benefit was observed with lopinavir–ritonavir treatment beyond standard care.” High quality randomised tri…
Just out today #COVID19 #Kaletra #treatment shows no benefit A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/ogIFQ5k5a7
RT @bealelab: @tulunsokit @rabpeel @NephJC Trial has just reported no benefit of Lopinavir/Ritonavir in NEJM. #nephjc https://t.co/CQZM79xh…
RT @FranciscoMarty_: #Lopinavir–#Ritonavir did not help patients #Hospitalized with Severe #COVID19. Please stop using #kaletra. How impo…
RT @bealelab: @tulunsokit @rabpeel @NephJC Trial has just reported no benefit of Lopinavir/Ritonavir in NEJM. #nephjc https://t.co/CQZM79xh…
RT @bealelab: @tulunsokit @rabpeel @NephJC Trial has just reported no benefit of Lopinavir/Ritonavir in NEJM. #nephjc https://t.co/CQZM79xh…
@FranciscoMarty_ taught me to wait for the randomized data before jumping on the train!
RT @ltmatthews: @DoctorRachael @AadiaMd
Trial of lopinavir/ritonavir in severe #COVID19 cases. Overall no benefit. But so important to be doing these types of studies. https://t.co/83sQQ8UZvS https://t.co/Zgx4rlQlZm
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 did not show any benefit I. This small study @SCCM @SCCMPresident @SapnaKmd @iamyourgasman @idpharmd @ChrisCarrollMD @l https://t.co/xN1Oonv3h8
"In hospitalized adult patients with severe #COVID19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care", reports this new publication from @NEJM #coronavirus https://t.co/zDyEZTXFbz
Ouch.
RT @NephJC: In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard…
#COVID2019AU “No benefit was observed with lopinavir–ritonavir treatment beyond standard care.” High quality randomised trial. Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://t.co/URCpav5ChT
RT @AndyBiotech: Here comes the data from first randomized trial for #COVID19 Unfortunately no benefit was observed with $ABBV lopinavir–…
RT @ISARIC1: 📢🆕🆕🆕NEW: first clinical trial of Lopinavir–Ritonavir in adults hospitalized with severe #COVID19 @PeterHorby co-author via…
RT @bealelab: @tulunsokit @rabpeel @NephJC Trial has just reported no benefit of Lopinavir/Ritonavir in NEJM. #nephjc https://t.co/CQZM79xh…
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…
In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir–ritonavir treatment beyond standard care. #NephJC
RT @CarlosdelRio7: A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | No benefit observed in #COVID19 in these pa…